FAK deletion accelerates liver regeneration after two-thirds partial hepatectomy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shang, Na ^a   Arteaga, Maribel ^a   Chitsike, Lennox ^a   Wang, Fang ^a   Viswakarma, Navin ^a   Breslin, Peter ^b,c   Qiu, Wei ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989347254     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34316     Document Type: Article

References (46)

1. Michalopoulos, G. K. Liver regeneration. Journal of cellular physiology 213, 286-300 (2007).
2. Michalopoulos, G. K. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 176, 2-13 (2010).
3. Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 7, 1513-1523 (1996).
4. Borowiak, M. et al. Met provides essential signals for liver regeneration. Proceedings of the National Academy of Sciences of the United States of America 101, 10608-10613 (2004).
5. Natarajan, A., Wagner, B. & Sibilia, M. The EGF receptor is required for efficient liver regeneration. Proceedings of the National Academy of Sciences of the United States of America 104, 17081-17086 (2007).
6. Jackson, L. N. et al. PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. American journal of physiology. Gastrointestinal and liver physiology 294, G1401-G1410 (2008).
7. Talarmin, H. et al. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Molecular and cellular biology 19, 6003-6011 (1999).
8. Li, W., Liang, X., Kellendonk, C., Poli, V. & Taub, R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. The Journal of biological chemistry 277, 28411-28417 (2002).
9. Speicher, T. et al. Knockdown and knockout of beta1-integrin in hepatocytes impairs liver regeneration through inhibition of growth factor signalling. Nature communications 5, 3862 (2014).
10. Apte, U. et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 50, 844-851 (2009).
11. Mitra, S. K., Hanson, D. A. & Schlaepfer, D. D. Focal adhesion kinase: in command and control of cell motility. Nature reviews. Molecular cell biology 6, 56-68 (2005).
12. Zhao, X. & Guan, J. L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Advanced drug delivery reviews 63, 610-615 (2011).
13. Schlaepfer, D. D., Hauck, C. R. & Sieg, D. J. Signaling through focal adhesion kinase. Progress in biophysics and molecular biology 71, 435-478 (1999).
14. Shang, N. et al. FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesis. Hepatology (2014).
15. Gilmore, A. P. & Romer, L. H. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Molecular biology of the cell 7, 1209-1224 (1996).
16. Frisch, S. M., Vuori, K., Ruoslahti, E. & Chan-Hui, P. Y. Control of adhesion-dependent cell survival by focal adhesion kinase. The Journal of cell biology 134, 793-799 (1996).
17. Lietha, D. et al. Structural basis for the autoinhibition of focal adhesion kinase. Cell 129, 1177-1187 (2007).
18. Schaller, M. D. et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Molecular and cellular biology 14, 1680-1688 (1994).
19. Zaret, K. S. & Grompe, M. Generation and regeneration of cells of the liver and pancreas. Science 322, 1490-1494 (2008).
20. Rojas, M., Yao, S. & Lin, Y. Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cellpermeable peptide mimicking phosphorylated EGF receptor. The Journal of biological chemistry 271, 27456-27461 (1996).
21. Tomas, A., Futter, C. E. & Eden, E. R. EGF receptor trafficking: consequences for signaling and cancer. Trends in cell biology 24, 26-34 (2014).
22. Kiso, S. et al. Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology 124, 701-707 (2003).
23. Dateoka, S., Ohnishi, Y. & Kakudo, K. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer. Medical molecular morphology 45, 91-97 (2012).
24. Kunami, N. et al. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia. Anticancer research 31, 2483-2488 (2011).
25. Patterson, C. et al. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. The Journal of clinical investigation 98, 490-496 (1996).
26. Akerman, P. et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. The American journal of physiology 263, G579-G585 (1992).
27. Yamada, Y., Kirillova, I., Peschon, J. J. & Fausto, N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proceedings of the National Academy of Sciences of the United States of America 94, 1441-1446 (1997).
28. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990 (2005).
29. Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007).
30. Schwabe, R. F. & Brenner, D. A. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290, G583-G589 (2006).
31. Johnson, C. et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Translational gastrointestinal cancer 1, 58-70 (2012).
32. Avraham, H., Park, S. Y., Schinkmann, K. & Avraham, S. RAFTK/Pyk2-mediated cellular signalling. Cellular signalling 12, 123-133 (2000).
33. Sieg, D. J. et al. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK-cell migration. The EMBO journal 17, 5933-5947 (1998).
34. Weis, S. M. et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. The Journal of cell biology 181, 43-50 (2008).
35. Fan, H. & Guan, J. L. Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. The Journal of biological chemistry 286, 18573-18582 (2011).
36. Sonoda, Y. et al. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. The Journal of biological chemistry 275, 16309-16315 (2000).
37. Kurenova, E. et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Molecular and cellular biology 24, 4361-4371 (2004).
38. Zhang, H. M. et al. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kappaB signaling in intestinal epithelial cells. American journal of physiology. Cell physiology 290, C1310-1320 (2006).
39. Chen, S. Y. & Chen, H. C. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Molecular and cellular biology 26, 5155-5167 (2006).
40. Schultze, A. & Fiedler, W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert opinion on investigational drugs 19, 777-788 (2010).
41. Infante, J. R. & Chen, H. C. et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, 1577-1533 (2012).
42. Mitchell, C. & Willenbring, H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature protocols 3, 1167-1170 (2008).
43. Mitchell, C. & Willenbring, H. Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature protocols 9 (2014).
44. Qiu, W. et al. PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology 54, 1249-1258 (2011).
45. Arteaga, M. et al. Inhibition of SIRT2 suppresses hepatic fibrosis. American journal of physiology. Gastrointestinal and liver physiology 310, G1155-1168 (2016).
46. Shang, N. et al. FAK kinase activity is required for the progression of c-Met/beta-catenin-driven HCC. Gene expression 310 (2016).